Phathom Pharmaceuticals, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone Q4 filing; quarterly figures below are unaudited. The company is a clinical-stage biopharmaceutical developer, with no products approved for sale and no product revenue.
Business context and development
Phathom licensed U.S., European and Canadian rights to vonoprazan from Takeda in May 2019. The drug is a potassium-competitive acid blocker being developed for erosive esophagitis and H. pylori infection. The company began pivotal Phase 3 trials for both indications in Q4 2019. Takeda reported more than $500 million in vonoprazan sales in its fourth full year in Japan; those sales are not Phathom revenue.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $20.4 million | $0.02 million |
| Acquired in-process R&D expense | $78.9 million | None |
| General and administrative expense | $6.9 million | $1.2 million |
| Operating loss | $106.2 million | $1.2 million |
| Net loss | $255.1 million | $1.3 million |
| Operating cash used | $36.5 million | $1.0 million |
| Cash and cash equivalents, year-end | $243.8 million | $0.9 million |
| Working capital, year-end | $251.9 million | $(1.3) million |
| Total liabilities, year-end | $29.2 million | $2.2 million |
There are no meaningful product margins because Phathom had no sales. The FY2019 net loss included substantial noncash fair-value charges: $96.3 million for warrant liabilities and $49.5 million for convertible notes. The $78.9 million in-process R&D charge reflected the Takeda license acquisition and included cash, stock and warrant consideration; it was not equivalent to cash R&D spending.
FY2019 investing cash outflow was $25.3 million, primarily for the Takeda license. Financing provided $304.6 million, including $191.5 million of net IPO proceeds, $88.3 million of net convertible-note proceeds and $24.8 million of net bank-debt proceeds. Year-end debt principal was $25 million. In March 2020, Phathom drew a further $25 million under its facility. Management stated that available cash was expected to fund operations for at least 24 months; that estimate is forward-looking and dependent on assumptions.
Material changes versus the prior period
- Operations expanded from a newly formed company to an active Phase 3 developer; R&D expense rose to $20.4 million from minimal spending in 2018.
- The May 2019 Takeda license generated $78.9 million of acquired in-process R&D expense and added contingent sales milestones of up to $250 million, plus tiered royalties in the low double digits to mid-teens on licensed-product sales.
- The October 2019 IPO raised approximately $191.5 million net. Convertible notes converted into 6.1 million common shares immediately before the IPO.
- Net loss rose sharply, principally because of the license-related charge and noncash fair-value remeasurements. Cash used in operations also increased as clinical and corporate activities commenced.
Outlook, risks and unusual items
- Management expected top-line results from both Phase 3 trials in 2021 and, if successful, regulatory submissions for H. pylori in 2021 and erosive esophagitis in 2022. These are plans, not assured outcomes.
- In March 2020, the company paused randomization of new patients in both trials because of COVID-19 disruptions, travel restrictions and limits on endoscopies required by the studies. Management maintained its expected 2021 data timing, while acknowledging possible delays, cost increases and other impacts.
- Vonoprazan had QIDP and Fast Track designations for specified H. pylori regimens; these do not assure approval or faster review. Japan post-marketing information included extremely rare serious skin and blood-cell reactions and hepatic events; safety and efficacy in Phathom’s Western Phase 3 trials remained unproven.
- Key risks include dependence on one unapproved product candidate, clinical and regulatory uncertainty, trial enrollment and pandemic disruption, reliance on Takeda for clinical supply, future commercial manufacturing and substantial future funding needs. Commercial success also depends on pricing, reimbursement, competition from generic PPIs and market acceptance.
- Debt is secured by substantially all assets other than intellectual property and specified assets, carries a floating rate and includes covenants and a final payment fee. The company reported covenant compliance at December 31, 2019. There were no material legal proceedings reported.
Important facts for investors to verify
- Cash runway assumptions, subsequent use of cash, the March 2020 $25 million loan draw and updated debt service terms.
- Trial restart, enrollment and endoscopy capacity, final data timing, and whether the FDA and EMA accept the trial designs and results.
- Vonoprazan’s safety profile in the target populations, including the rare post-marketing events disclosed from Japan.
- Takeda license economics, royalty and milestone triggers, commercial supply arrangements, and the scope and duration of patent protection.
- Whether potential product pricing and payer coverage can support commercial adoption against low-cost generic therapies.